Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Pfizer (Canada)
h-index: 57
Total citations: 14,506
Total papers: 623
Homepage:
http://www.pfizer.ca/
Recent papers from Pfizer (Canada)
Benefit-risk trade-offs among patients and providers selecting advanced therapy for moderate-to-severe ulcerative colitis
Clinical and Translational Gastroenterology · 2026
A Narrative Review of the Role of Adjuvants in Adult RSV Vaccines
Vaccines · 2026
Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis
Rheumatology and Therapy · 2026
Population Pharmacokinetics and Exposure–Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non‐Muscle Invasive Bladder Cancer and Other Solid Tumors
The Journal of Clinical Pharmacology · 2026
A consensus framework for digital twin development in lyophilization
AAPS Open · 2026
Describing the clinical outcomes and treatment landscape for male haemophilia A and B patients in a real-world setting across Europe and the United States
Blood Coagulation & Fibrinolysis · 2026
A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma
British Journal of Cancer · 2026
Long-term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase 2 Results from Double-blind and Open-Label Extension Studies
The Journal of Rheumatology · 2026
Bowel Urgency in Ulcerative Colitis Is Associated With Clinical Endpoints, Health-Related Quality of Life, and Biomarkers: Data From the Etrasimod ELEVATE UC 52 Trial
Crohn s & Colitis 360 · 2026
Clostridioides difficile Infection (CDI) Disease Burden (Cases, Hospitalizations, and Deaths) in Mainland China: A Systematic Literature Review
Infectious Disease Reports · 2026
The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program
Therapeutic Advances in Gastroenterology · 2026
Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study
Research and Practice in Thrombosis and Haemostasis · 2026
Safety of BNT162b2 COVID-19 Vaccine in Pregnancy: A Systematic Review
Infectious Diseases and Therapy · 2026
Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Dermatology and Therapy · 2026
Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First‐Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries
United European Gastroenterology Journal · 2026
Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis
Dermatology and Therapy · 2026
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial
Clinical Gastroenterology and Hepatology · 2026
Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): An in-depth safety analysis of HER2CLIMB-05.
Journal of Clinical Oncology · 2026
The Global Burden of Human Metapneumovirus in High-Risk Adults: A Systematic Literature Review and Meta-Analysis
Journal of Epidemiology and Global Health · 2026
Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States
Therapeutic Advances in Gastroenterology · 2026